Who
Vlad Coric
Director
Company insider
Files Form 4 as: Director, Royalty Pharma; Chief Executive Officer, Biohaven; Director, Veradermics; Director, Revance Therapeutics; Chief Executive Officer, Biohaven Pharmaceutical Holding Co.
In numbers
- Trades disclosed
- 239
- Buys
- 10
- Sells
- 8
- Bought
- $41.7M
- Sold
- $11.2M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 31 Oct 2017
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —4,545 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —4,545 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —550,000 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —550,000 at $0.00 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Code C | —33,706 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —33,706 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —33,706 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —148,794 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —148,794 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —78,075 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —78,075 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —117,112 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Code C | —33,706 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Code C | —148,794 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —33,706 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —33,706 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —148,794 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —148,794 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —78,075 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —78,075 | filing |
News
Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in... - Pharma / BioTech / Nutrition - ONO Pharmaceutical Co., LtdBHVN · newswiretoday.com · 9 Oct 2026Biohaven Licenses IgG Degrader Portfolio To Ono Pharma In Key Asian MarketsBHVN · rttnews.com · 8 Oct 2026
0 headlines in the last 90 days name Vlad Coric; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.